HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors — Stella

Recruiting

Back to Advanced Solid Tumors trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

West China Hospital of Sichuan University, Chengdu, Sichuan

Key details

Phase

Very early testing

Sponsor

HighField Biopharmaceuticals Corporation

Enrollment target

~10 participants

Started

June 2025

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov